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Abstract: The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and 
histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 
3 ﬁ  brosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 
2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low 
(ALT   30 IU/l); moderate (ALT  30  80 IU/l) and high (ALT   80 IU/l) ALT groups. Eleven patients were re-treated 
with IFN. During the follow-up period of 12 years, HCC developed in 26 patients with an average annual incidence of 3.9%. 
Biochemical responders to initial IFN therapy (n = 8) and those re-treated with IFN (n = 10), except 1, did not develop HCC. 
Cox regression analysis to evaluate risk factors for HCC occurrence, found development of Liver Cirrhosis within 3 years 
of initial IFN therapy(P = 0.05) and the 3 year annual average ALT post initial IFN therapy (P = 0.033) to be signiﬁ  cant. 
The 12 year annual average ALT was also found to be signiﬁ  cantly related to HCC occurrence (P = 0.016), on univariate 
analysis. Patients belonging to the continuously low ALT group (ALT   30 IU/l for  3 years), did not develop HCC or 
receive IFN re-treatment. In CHC patients with F3, after initial IFN therapy, keeping ALT continuously low, below 30 IU/l 
for 3 years or more seems important. Continuing treatment with anti-inﬂ  ammatory drugs along with subsequent IFN 
re-treatment may prevent or delay HCC even in elderly patients.
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Background
Chronic infection with HCV (ongoing HCV infection for 6 months or more) is a leading cause of chronic 
liver disease, cirrhosis (LC) and hepatocellular carcinoma (HCC). In Japan the number of deaths annu-
ally due to HCC exceeds 30,000 (1). The risk of HCC development has been reported to be high in 
HCV-infected patients who have biochemically and histologically active chronic hepatitis, suggesting 
that necro-inﬂ  ammation and associated regenerative processes play a pivotal role in hepatic carcinogen-
esis (2,3,4). Patients with advanced ﬁ  brosis (stage 3 or stage 4) are reported to be at a higher risk of 
development of HCC (5) and HCC patients have a signiﬁ  cantly higher level of mean serum ALT than 
non-HCC patients (6). In long term follow-up studies, patients with persistently low or normal ALT 
develop HCC less frequently than those with persistently high ALT (5,7). Interferon (IFN) is an approved 
anti-viral agent known to be effective against HCV infection, by eliminating HCV and reducing ALT 
activity (8 ∼ 13). However, only 50% of patients achieve sustained virological response (undetectable 
HCV RNA 6 months after the end of IFN treatment (14 ∼ 17), the therapy regime extending from a 
minimum period of 4 weeks to a maximum period of 24 weeks. Immediate re-treatment with IFN or 
other anti-inﬂ  ammatory drugs in patients who do not respond to initial IFN therapy, is sometimes effec-
tive. In our previous study (18) we followed 48 chronic hepatitis C (CHC) patients who were either 
partial responders PR (ALT between 30–80 IU/l); or non-responders: NR (ALT  80 IU/l, longer than 6 
months) to initial IFN therapy, and were given anti-inﬂ  ammatory drugs (19) such as Stronger Neo-
Minophagen (SNMC), Ursodeoxy-cholic acid (UDCA) and Shosaioko-to, to subside inﬂ  ammation and 
suppress ALT activity. During the 6 year follow-up period, 7 patients developed HCC. Maintaining ALT 
below 80 IU/l was found to prevent or delay HCC occurrence. In this study, we followed 55 HCV-infected 382
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individuals with ﬁ  brosis stage 3 (F3) for a period 
of 12 years, in order to assess which factors were 
important in HCC development, in these F3 patients 
when followed up for more than 10 years. Based 
on recent studies, the low ALT group was redeﬁ  ned 
as ALT   30 IU/l. from  80 IU/l as in our previous 
paper. All patients were divided into low, moderate 
and high ALT groups.
Patients and Methods
Fifty ﬁ  ve CHC patients with F3 (male: 24; female: 
31) who underwent initial IFN therapy were fol-
lowed up from 1994 to 2005, at Kawasaki Hospital 
Okayama and Okayama Medical School Hospital, 
Okayama, Japan. The end-point of the study was 
the development of HCC. The total follow-up period 
was divided into 2 parts. The ﬁ  rst half and second 
half each consisted of 6 years, respectively. The 
average observation period was 9.8 ± 2.3 years. The 
inclusion criteria for patients was; HCV RNA 
positive in sera; histologically diagnosed as CHC 
with F3, according to the classiﬁ  cation of Knodell 
et al. and V. J Desmet (20–21); following initial IFN 
therapy, response was either complete biochemical 
response, (BR: ALT level   30 IU/l); partial (PR: 
ALT between 30–80 IU/l); or non-response (NR: 
ALT   80 IU/l), longer than 6 months post IFN. 
Patients who were sustained virological responders 
to IFN (HCV RNA negative in sera; ALT   30 IU/l) 
over 6 months and had pre-existing HCC, were 
excluded. During the 12 year follow-up period, in 
the out-patient clinic patients underwent ultrasonog-
raphy (US) every 6 months and on detection of liver 
cirrhosis (LC), every 3 months. Other imaging 
techniques such as computed tomography (CT), 
magnetic resonance imaging (MRI) were performed 
routinely once a year and when required. Serum 
ALT activity and other liver function tests were 
performed monthly. On suspicion of HCC, further 
imaging techniques, angiography and liver biopsy 
was carried out to conﬁ  rm HCC diagnosis. The end-
point of the study was the development of HCC. 
Informed consent was obtained from all patients 
prior to this study. This study was performed under 
the approval guidelines of the ethical committee.
Laboratory data analysis
The annual average serum ALT, PLT (platelet count) 
and other markers, from the beginning of the study 
till the end were calculated in all patients.
An annual average ALT ( 30 IU/l) was 
considered low, while ALT (30–80) IU/l was taken 
as moderate, with ALT ( 80 IU/l) being consid-
ered as high. In all patients, at least a minimum of 
4–5 and a maximum of 12 ALT values/year were 
available, during the follow-up period. The 
decrease in PLT count over 12 years was calculated 
from the average PLT at the beginning of the study 
to the end of the study or on HCC development.
Additional therapeutic procedures
a) Anti-inﬂ  ammatory drug therapy.
b) Re-treatment with IFN or IFN and Ribavirin 
combination.
c) Supplementary Vitamin E.
d) All PR and NR patients underwent anti-
inﬂ  ammatory drug therapy such as; SNMC; 
2–3 ampules (20 ml/ampule), 3 times/week and 
increased to a maximum of 4–5 ampules, 4–6 
times a week}: UDCA; 300–600 mg/day to a 
maximum dose of 900 mg/day, with most 
patients receiving 600 mg/day and Shosaiko-to 
(7 g/day). Depending upon the ALT level, doses 
were readjusted accordingly. A total of 11 
patients (BR = 2; PR = 5; NR = 4) patients were 
further re-treated with either IFN, PEG Intron 
(1.5 μg/kg once a week) or in combination with 
Ribavirin (600 ∼ 1,000 mg/day). Unfortunately, 
all patients could not be re-treated with pegin-
terferon and ribavirin due to costly reasons at 
the beginning of the study when all treatments 
were not covered by the health insurance and 
secondly due to side effects leading to patient 
reluctance. Supplementary Vitamin E therapy 
was given at a dose of 600 mg/day to a total of 
13 patients.
Statistical Analyses
The statistical analysis was carried out in two parts. 
At ﬁ  rst, univariate analysis was performed using 
the statistical package SAS version 6.12. Next, to 
analyze the “time to event” clinical data, a Cox 
Regression Model was made. The following 
5 covariates were entered into the model:
a) The initial IFN response.
b) The mean ALT over 3 years post initial IFN 
therapy.
c) The presence of cirrhosis within 3 years post 
initial IFN therapy.383
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d) Age and sex (known to affect the risk of HCC 
development) Results were expressed in mean 
±S.D.
Results
The baseline characteristics of all 55 patients are 
given in Table 1. Over a span of 12 years (average 
9.8 ± 2.3 years), 26 out of 55 patients developed 
HCC (NR = 20; PR = 6). No BR patient nor IFN 
retreated patient, except one, developed HCC. The 
annual incidence of HCC was 3.9%. All HCC and 
non-HCC patients are compared in Table 2. 
Univariate analysis to ﬁ  nd the best predictor of HCC 
occurrence showed initial IFN response (P = 0.013), 
development of liver cirrhosis within a year of 
follow-up (P = 0.0006), and the 12 year annual aver-
age ALT activity (P = 0.0034), to be signiﬁ  cantly 
related to HCC development. The Cox Proportional 
Hazard model, using 5 covariates, found the develop-
ment of liver cirrhosis within 3 years of initial IFN 
therapy (Hazard Ratio: 3.39; 95% CI: 0.88–5.09; 
P = 0.05), and the 3 year annual average ALT activity, 
post initial IFN therapy (Hazard Ratio: 2.24; 95% 
CI: 1.07–4.71; P = 0.033), signiﬁ  cantly related to 
HCC occurrence (Table 3). The IFN response, 
age and sex remained insignificant. When the 
7 early HCC and 19 late HCC patients were compared 
(Table 4), development of liver cirrhosis within 
a year of follow-up (P  = 0.0028) was the 
only significant variable associated with HCC 
development. The change in annual average ALT 
during the follow-up period in HCC patients in 
shown in Figure 1. Data is represented in order of 
early to late HCC from the top. While the early HCC 
group had no patient from the “L” ALT group (annual 
average ALT   30 IU/l), 8 (42%) patients in the late 
HCC group presented with low ALT one or more 
times during the follow-up period. Seventeen HCC 
patients died during the follow-up period of which, 
14 (82.4%) were NR to initial IFN therapy. Figure 2 
shows the annual average ALT pattern in the 
Table 1. Patient Characteristics at baseline.
 n  = 55
Age in years  60.8 ± 8.2
Sex (M/F)  (24/31)
H/O B.T (+) 43.60%
H/O L.D (+) 12.70%
H/O Alcohol (+) 7%
IFN response: BR/PR/NR  (8/16/31)
Genotype 1b  76%
HCV RNA   1Meq/ml  61.00%
ALT(IU/l)
(L   30 INU; M 30–80 INU/l; H   80 INU)  11/20/24
PLT (× 104 μl) 12.3  ± 3.6
Abbreviations: M/F: male/female; H/O: history of; BT: blood transfu-
sion; LD: liver disease; IFN: interferon; BR: biochemical responder; 
PR: partial rresponder; NR: non-responder; ALT: alanine aminotrans-
ferase; L: low; M: moderate; H: high; PLT: platelet; Data are 
mean ± SD.






Age (in years) 61.5 ± 7.1 60.2 ± 9.1 NS
Sex (M/F)  (12/14) (12/17) NS
H/O B.T (+) 53.80% 34.50% NS
H/O L.D (+) 7.70% 17.20% NS
H/O Alcohol (+) 5% 10.30% NS
IFN response: BR/PR/NR (0/6/20) (8/10/11) 0.0131*
Genotype 1b/other (20/6) (20/9) NS
HCV RNA   1Meq/ml 69.20% 55.20% NS
LC within '94 30.80% 6.90% 0.0006*
Biochemical values
12 year average ALT ('94–'05) (4/17/5) (11/14/4) 0.0034*
( 30 INU; 30–80 INU/l;  80 INU)
Decrease in PLT in 12 years ('94–'05) 0.34 ± 0.31 0.33 ± 0.44 NS
Abbreviations: M/F: male/female; H/O: history of; BT: blood transfusion; LD: liver disease; IFN: interferon; BR: biochemical responder; 
PR: partial responder; NR: non-responder; ALT: alanine aminotransferase; PLT: platelet; HCC: hepatocellular carcinoma.
Note: *statistically signiﬁ  cant by logistic regression analysis; Data are mean ± SD.384
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non-HCC group throughout the follow-up period. 
Five patients had continuously low ALT ( 30 IU/l) 
for 3 years or more and did not receive IFN re-treat-
ment. Within the transient ALT group (ALT 30–80 
IU/l: n = 24), 10 patients (41.7%) received IFN re-
treatment. Three patients in this group died before 
completion of study. Cause of death was suicide in 
one patient and liver failure in the other two.
Discussion
Chronic HCV infection represents one of the major 
health problems throughout the world.   Approxi-
mately 20%–30% of CHC patients will progress to 
LC, hepatic decompensation and HCC (22 ∼ 24). 
In Japan, about 6%–8% HCV associated LC 
patients are assumed to be at a high risk for HCC 
development (25), that is to say, patients who are 
anti HCV positive and have reached the cirrhotic 
stage, have a greater possibility of developing HCC. 
Even in the non-cirrhotic group, the annual inci-
dence of HCC increased from 0.07% in F0 and F1 
to 2.2% in F3 patients with non-sustained virologic 
response to initial IFN therapy (5). Thus the F3 
group of CHC patients are a vulnerable group who 
need to be monitored closely. High risk factors need 
to be demarcated in this group, in order to better 
understand how to prevent or delay HCC develop-
ment. Some studies have shown that persistently 
high ALT is a major risk factor for HCC (26). 
Normalization of ALT with IFN (even without HCV 
eradication) has led to a less likelihood of HCC 
occurrence (27). In our previous study (18) we 
reported CHC patients with F3 who have a con-
tinuous elevation of ALT ( 80 IU/l) for 2 years or 
more are at a high risk of developing HCC. Sup-
pressing ALT activity below 80 IU/l by initial IFN 
followed by anti-inﬂ  ammatory drugs, can prevent 
or delay HCC occurrence. In this study we aimed 
to ﬁ  nd out whether even after a prolonged follow-
up period (12 years), the ALT activity was still 
important in HCC development, as we have seen 
in an earlier study. In accordance with a study con-
ducted by Okanoue et al. (28), the lower limit of 
ALT was adjusted to  30 IU/l and similar outcomes 
were observed in terms of HCC development. The 
Table 3. Cox regression analysis to determine risk 
factors of HCC occurrence (n = 55).
Covariate Hazard  95%  CI  P  value
 Ratio 
Age 1.02  0.47–1.01  0.468
Sex 1.01  0.47–2.20  0.976
Initial 1.89  0.84–4.30  0.125
IFN response 
LC within 3 years   3.39  0.88–5.09  0.05
of initial IFN therapy
3 year Avg. ALT  2.24  1.07–4.71  0.033
following intial IFN
therapy
Abbreviations: CI: conﬁ  dence interval; IFN: interferon; LC: liver 
corrhosis; ALT: alanine aminotransferase.
Table 4. Comparison of the clinical proﬁ  le of early HCC and late-HCC patients with stage 3 ﬁ  brosis (n = 26).
Early HCC n = 7 Late HCC n = 19 P value
Age at 94 63.3 ± 6.2 60.8 ± 7.5 NS
Sex (M/F) (3/4) (9/10) NS
H/O B.T (+) 57.10% 52.60% NS
H/O L.D (+) 5.20% 5.30% NS
H/O Alcohol (+) 0% 5.30% NS
IFN response: PR/NR (2/5) (4/15) NS
Genotype 1b/other (5/2) (21/6) NS
HCV RNA   1Meq/ml 57.10% 73.70% NS
LC within '94 85.70% 10.50% 0.0028*
Biochemical values
Avg. ALT at end pt. HCC(L/M/H) 
( 30 INU/l; 30–80 INU/l;  80 INU/l)
(0/4/3) (4/13/2) NS
Decrease in PLT till HCC ('94–'05) 0.24 ± 0.36 0.37 ± 0.29 NS
Abbreviations: HCC: hepatocellular carcinoma; M/F: male/female; H/O: history of; BT: blood transfusion; LD: liver disease; IFN: interferon; 
PR: partial responder; NR: non-responder; PLT: platelet; LC: liver corrhosis; ALT: alanine aminotransferase.
Note: *statistically signiﬁ  cant; Data are mean ± SD.385
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continuously low ALT group (n = 5) did not develop 
HCC after 12 years, even in elderly patients, who 
did not receive IFN re-treatment. Though the 
number of patients with continuously low ALT 
( 30 IU/l ) are few in this study, suppressing 
ALT   30 IU/l with anti-inﬂ  ammatory drugs post 
IFN, may partly contribute in delaying HCC occur-
rence in patients, who are NR to initial IFN therapy. 
When HCC and non HCC patients were compared, 
none of the BR patients developed HCC. The initial 
IFN response, LC stage at beginning of study and 
the 12 year annual average ALT were signiﬁ  cantly 
related to HCC occurrence. Analyzing the data with 
the use of the Cox Proportional Hazard model, LC 
within 3 years of initial IFN therapy and the 3 year 
annual average ALT post initial IFN, were found 
to be signiﬁ  cantly related to HCC occurrence. 
Though in previous studies, populations at high risk 
of developing HCC in HCV infected patients 
include those of older age, male sex, non-response 
to initial IFN (25), in the present study, the average 
age of patients in both the HCC and non-HCC group 
was almost same (61.5 ± 7.1 : 60.2 ± 9.1) years and 
there was no male predominancy in either group. 
However, HCC developed in 19 patients (almost 3 
times the number) in the latter 6 years compared to 
7 HCC patients in the first 6 years. Perhaps, 
advancement in age may have accelerated disease 
progression to HCC. In one of our previous studies 
(29) we found that oxidative stress markers such as 
reactive oxygen molecules (ROM) were signiﬁ  -
cantly higher in HCV patients than controls and 
increased with age (P   0.05). Since the non-HCC 
patients were also elderly, some other host factor 
in addition to oxidative damage, must be delaying 
HCC in this group. Studies (30) have shown that 
IFN re-treatment aids in re-achieving biochemical 
response in CHC patients. In 10 out of 11 patients 
in this study who were re-treated with IFN, IFN 
re-treatment might have helped to maintain a low 
ALT status or prevented further elevation of ALT, 
but a bigger patient population of IFN re-treated 
patients are required to establish this hypothesis. 
Efﬁ  cacy of IFN re-treatment in BR, PR and even 
NR patients have been documented (31–32). As for 
the patient who developed HCC, irrespective of 
Figure 1. Change in annual average ALT during the follow-up period in HCC patients.
Sex IFNRAge at 1994 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
FN R 7 0
MN R 6 5 early HCC within 1st. 6 years
MN R 5 2 n = 7
FN R 6 2
FP R 6 7
FP R 5 9
MN R 6 8
MP R 6 2
FN R 6 3
FN R 6 8
MN R 6 2
FN R 5 6
MN R 4 6 late HCC after 6 years
FN R 6 4 n = 19
MP R 6 8
MN R 6 3
MP R 7 4
FN R 5 9
FN R 4 6
FN R 6 0
MP R 5 6
FN R 6 7
MN R 5 3
MN R 6 6
FN R 5 4
FN R 6 8
F = female; M = male; IFNR = Interferon Response; BR = complete biochemical response; PR = partial response; NR = non response Annual average ALT values;
      low <30IU/l;       moderate >30 < 80 IU/l;       high > 80 IU/l;     died during follow-up period.
HCC patients (n = 26)386
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IFN re-treatment, it may be assumed that since the 
patient developed HCC within 18 months of IFN 
treatment, perhaps there was a pre-existing HCC, 
prior to IFN therapy for which HCC could not be 
prevented even with additional IFN. In the remain-
ing 14 non-HCC patients, judging by their annual 
average ALT pattern, maintaining ALT below 
 80 IU/l on most occasions seemed to have con-
tributed to HCC prevention until now. It remains 
to be seen how this non-HCC group progresses 
within the next 5 years. Probably the rate of progres-
sion to HCC will increase further. Continuously 
low ALT, biochemical or partial response to initial 
IFN therapy and IFN re-treatment may have pre-
vented HCC, in these patients (33∼35). From this 
study, it is apparent that long suppression of ALT 
below ( 30 IU/l) may assist in lowering or delay-
ing HCC occurrence in CHC patients 
with F3. Additional re-treatment with IFN, 
anti-inﬂ  ammatory drugs and to some extent supple-
mentary Vitamin E treatment (36) could have aided 
in lowering ALT. Though not signiﬁ  cant, it was 
found that of the 13 patients who received 
supplementary Vitamin E treatment, only 2 devel-
oped HCC. Thus, keeping ALT activity continu-
ously low ( 30 IU/l ), demarcating the moderately 
at risk ALT group (30–50 IU/L) and initiating IFN 
re-treatment and other supplementary treatments, 
even in elderly, non-responder patients, may be 
helpful in prevention or delay of HCC occurrence. 
However, small patient population and fewer number 
of IFN re-treated patients makes it difﬁ  cult to decide 
the actual efﬁ  cacy of IFN re-treatment in contribut-
ing to low ALT values, in this study. A bigger popu-
lation of both IFN re-treated patients and continuously 
low ALT group needs studied further studies.
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